Profile data is unavailable for this security.
Mergers & acquisitions
Acquired company | LLY:NYQ since announced | Transaction value |
---|---|---|
Mablink Bioscience SAS | 23.25% | -- |
POINT Biopharma Global Inc | 41.19% | 1.38bn |
Versanis Bio Inc | 74.83% | 1.93bn |
Emergence Therapeutics AG | 65.69% | 8.33m |
Sigilon Therapeutics Inc | 65.69% | 316.64m |
Data delayed at least 15 minutes, as of May 10 2024 21:10 BST.
Holder | Shares | % Held |
---|---|---|
Western Asset Management Company DTVM Ltda.as of 31 Dec 2023 | 206.43k | 0.00% |
Bram Bradesco Asset Management S/A DTVMas of 31 Dec 2023 | 53.86k | 0.00% |
Safra Asset Management Ltda.as of 31 Dec 2023 | 49.80k | 0.00% |
Warren Brasil Gest�o e Administra��o e Recursos Ltda.as of 31 Dec 2023 | 10.76k | 0.00% |
BTG Pactual WM Gest�o de Recursos Ltda.as of 31 Dec 2023 | 2.71k | 0.00% |
XP Allocation Asset Management Ltda.as of 31 Dec 2023 | 1.38k | 0.00% |
BB Gest�o de Recursos DTVM SAas of 31 Dec 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 09 May 2024Source: FactSet Research Systems Inc.